Neurology · South Carolina
Neurology studies in South Carolina
35 studies have at least one recruiting site in South Carolina. Neurology research spans migraine, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, stroke and nerve pain.
35 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteers
A Study to Evaluate the SENSE Device's Ability to Detect TBI
Sense Diagnostics, LLC
- Location
- Charleston, SC + 5 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Greenville, SC + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC
- Location
- Greenville, SC + 24 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC
- Location
- Greenville, SC + 18 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 2
Strategy for Improving Stroke Treatment Response
Translational Sciences, Inc.
- Location
- Charleston, SC + 37 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
- Location
- Charleston, SC + 67 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Charleston, SC + 57 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
Regeneron Pharmaceuticals
- Location
- Anderson, SC + 42 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Anderson, SC + 35 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Greenville, SC + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Neuron23 Inc.
- Location
- Charleston, SC + 43 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
Study of EVO756 in Adults With Migraine
Evommune, Inc.
- Location
- Charleston, SC + 32 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
MapLight Therapeutics
- Location
- Port Royal, SC + 32 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2/Phase 3
A Study of Buntanetap in Participants With PD
Annovis Bio Inc.
- Location
- Charleston, SC + 26 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 2/Phase 3
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
DiaMedica Therapeutics Inc
- Location
- Greenville, SC + 35 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Greenville, SC + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Dompé Farmaceutici S.p.A
- Location
- Charleston, SC + 13 other US sites
- Eligibility basics
- Ages 50–80
- RecruitingPhase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Novartis Pharmaceuticals
- Location
- Greenville, SC + 42 other US sites
- Eligibility basics
- Ages 40–70
- RecruitingPhase 3
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
Oculis
- Location
- Charleston, SC + 3 other US sites
- Eligibility basics
- Ages 18–50
- RecruitingPhase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
- Location
- Charleston, SC + 39 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
BlueRock Therapeutics
- Location
- Charleston, SC + 33 other US sites
- Eligibility basics
- Ages 45–75
- Recruiting
Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study
Recross Cardio, Inc.
- Location
- Greenville, SC + 4 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Anderson, SC + 69 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
AbbVie
- Location
- Summerville, SC + 7 other US sites
- Eligibility basics
- Ages 18–70
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Why do memory studies need a study partner?
A partner can report day-to-day changes the participant may not notice. Each study explains what the partner is asked to do.